"LifeSeq Gold provides a comprehensive view of the human genome. It integrates EST, full-length and genomic sequence information, as well as mapping data. LifeSeq Gold contains over 100,000 genes including 50,000 novel genes not available anywhere else, and is comprised of more than 5 million sequences from nearly 1,000 different tissue libraries, representing an estimated 90 percent of all human genes." (from the 8:46 AM press release)
. . . 50,000 novel genes not available anywhere else . . . isn't that the long-term good news here, alongside the short-term bad news of a revenues/earnings shortfall? Especially when the increased expenses are largely a result of the management decision earlier this year to increase R&D spending to improve INCY's database and patent position..
And isn't this why all of the big pharmas (at least the current customers, and likely others) will feel the need to keep subscribing to expanded packages of INCY's databases and data management software, as well as for the reasons stated in the next paragraph:
"The genomic information, cDNA clones and bioinformatics tools contained in LifeSeq Gold will enable AstraZeneca researchers to manage the growing complexity of data related to the human genome and apply it to drug discovery and development."
On the other hand, I sure do hate all these "buying opportunities" in good companies where I've already done all or nearly all my buying!
--RCM |
